PD-L1 expression in cerebrospinal fluid for leptomeningeal metastasis from solid tumors: preliminary assessment of clinical implications.

ABSTRACT:

Background

Intrathecal immune checkpoint inhibitors have shown promise for leptomeningeal metastasis (LM). Programmed cell death ligand 1 (PD-L1) is currently the primary predictive biomarker for immunotherapy response. This study assessed the feasibility of PD-L1 detection via immunocytochemistry based on ThinPrep liquid-based cytology (LBC), explored its application in cerebrospinal fluid (CSF) from LM patients and preliminarily evaluated clinical implications.

Methods

Technical validation used six human tumor cell lines (lung, breast and gastric) with validated high/low PD-L1 expression, which were processed into ThinPrep LBC slides and cell block sections. PD-L1 immunocytochemistry and immunohistochemistry were performed using four antibodies (Dako 22C3, Ventana SP263, A

SUBMITTER: Pan Z 

PROVIDER: S-EPMC12515682 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature